Lv31
304 积分 2022-09-05 加入
The future of follicular lymphoma management: strategies on the horizon
4小时前
待确认
Treatment of relapsed and refractory follicular lymphoma: which treatment for which patient for which line of therapy?
4小时前
已完结
The present and future for CAR-T cell therapy in adult B-cell ALL
1个月前
已完结
Combined PET and ctDNA response as a predictor of POD24 for follicular lymphoma after first-line induction treatment
2个月前
已完结
Zanubrutinib, Obinutuzumab, and Venetoclax for First-Line Treatment of Mantle Cell Lymphoma with a TP53 Mutation
3个月前
已完结
High-Risk MCL: Recognition and Treatment
3个月前
已完结
Prognostic Biomarkers in MCL: Insights from the SHINE Trial on the impact of MCL35 score and TP53 Mutation Status
3个月前
已完结
Primary central nervous system lymphoma
3个月前
已完结
Bruton’s tyrosine kinase inhibitor zanubrutinib-based regimens in relapsed/refractory primary diffuse large B-cell lymphoma of the central nervous system
3个月前
已完结
Outcomes of CD19 CAR‐T therapy in central nervous system lymphoma: Insights from a multicentre experience
3个月前
已完结
皖公网安备34019202002308
